<DOC>
	<DOCNO>NCT01545336</DOCNO>
	<brief_summary>The main purpose clinical trial study safety efficacy anastrozole adult diagnose pulmonary arterial hypertension ( PAH ) . The study evaluate well drug tolerate . The study also evaluate anastrozole effect estradiol ( E2 ) hormone level , sex hormone , improve function low right chamber heart ( right ventricle ) .</brief_summary>
	<brief_title>Anastrozole Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Previous documentation mean pulmonary artery pressure &gt; 25 mm Hg pulmonary capillary wedge pressure ( left ventricular enddiastolic pressure ) &lt; 16 mm Hg PVR &gt; 3 WU time study entry . Diagnosis PAH idiopathic , heritable , drug toxininduced , associate connective tissue disease , congenital heart disease , portal hypertension , HIV infection . Most recent pulmonary function test FEV1/FVC &gt; 50 % AND either ) total lung capacity &gt; 70 % predict b ) total lung capacity 60 % 70 % predict mild interstitial lung disease computerize tomography scan chest Ability perform six minute walk test without limitation musculoskeletal function coordination . If female , postmenopausal state , define : &gt; 50 year old AND ) menstruate precede 12 month OR b ) folliclestimulating hormone ( FSH ) level ( &gt; 40 IU/L ) OR &lt; 50 year FSH ( &gt; 40 IU/L ) OR bilateral oophorectomy Informed consent Treatment estrogen antihormone therapy ( tamoxifen , fulvestrant , etc . ) WHO Class IV functional status History breast cancer Clinically significant untreated sleep apnea Leftsided valvular disease ( moderate mitral valve stenosis insufficiency aortic stenosis insufficiency ) , pulmonary artery valve stenosis , ejection fraction &lt; 45 % echocardiography Initiation PAH therapy ( prostacyclin analogue , endothelin1 receptor antagonist , phosphodiesterase5 inhibitor ) within three month enrollment ; dose must stable least 3 month prior Baseline Visit Hormone therapy Hospitalized acutely ill Renal failure ( creatinine &gt; 2.0 ) ChildPugh Class C cirrhosis Current recent ( &lt; 6 month ) chronic heavy alcohol consumption Current use another investigational drug ( nonFDA approve ) PAH Enrollment clinical trial within one month screen Age &lt; 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>